Main results
One trial was eligible for inclusion. All participants were age 60 years or over and had received a repeat prescription from their general practitioner of quinine for nighttime cramps in the preceding three months. This review includes data from only those participants who were advised to continue taking quinine. Forty-nine participants were advised to complete lean-to-wall calf muscle stretching held for 10 s three times per day. Forty-eight participants were allocated to a placebo stretching group. After 12 weeks, there was no statistically significant difference in recalled cramp frequency between groups. No "significant" adverse effect was reported. Limitations in the study's design impede interpretation of the results and clinical applicability.
Authors' conclusions
There is limited evidence on which to base clinical decisions regarding the use of non-drug therapies for the treatment of lower limb muscle cramp. Serious methodological limitations in the existing evidence hinder clinical application. There is an urgent need to carefully evaluate many of the commonly recommended and emerging non-drug therapies in well designed randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y

Non-drug therapies for lower limb muscle cramps
Lower limb muscle cramps are a common problem that can affect any person, but cramps mostly occur during exercise, at nighttime in older people, in pregnant women, in people with a neurological disease and during kidney dialysis. Non-drug treatments are described as being effective for the treatment of muscle cramps. Non-drug treatments include muscle stretching, physical exercise, avoidance of physical fatigue, massage, relaxation, heat therapy, weight loss, sensory nerve stimulation, ankle splints worn while sleeping, and changes to sleeping and sitting positions. We did not include invasive interventions such as surgery, acupuncture or dry-needling in this review.
Only one randomised trial has assessed the effectiveness of a non-drug treatment for lower limb muscle cramp. This trial evaluated daytime calf muscle stretching to prevent nighttime muscle cramp in adults age 60 years and over who had received a repeat prescription of quinine for nighttime cramps in the preceding three months. Forty-nine participants were advised to complete lean-to-wall calf muscle stretching held for 10 s three times per day. Forty-eight participants were allocated to a placebo stretching group. After 12 weeks, there was no statistically significant difference in the frequency of cramps, as recalled by the participants, between groups. No "significant" adverse effect was reported. Owing to serious limitations in the design of the trial, it is impossible to determine from the available evidence whether or not calf muscle stretching can prevent recurrent lower limb muscle cramp.
Further research is required to determine the effectiveness of non-drug treatments for lower limb muscle cramp.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Calf muscle stretching versus placebo stretching for lower limb muscle cramps Patient or population: patients with lower limb muscle cramps
Settings: general practice
Intervention: lean-to-wall calf muscle stretching held for 10 s, three times per day versus placebo (sham) stretching Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality:
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality:
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality:
We are very uncertain about the estimate.
1
Participants were allowed to swap intervention groups after six weeks. Trial authors provided only 12-week follow-up data. Allowed treatment changes included: discontinuation of quinine, discontinuation of any form of stretching exercise and, if the participant was initially allocated to placebo stretching group, beginning the stretching exercise program. It is not known how many of the participants within the stretching and placebo stretching groups included in this review modified their intervention at six weeks.
2
Total sample size is lower than the calculated optimal information size and the 95% CI includes the point of no effect and the upper limit crosses the minimal important difference for benefit. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D Description of the condition
Muscle cramps are sudden, involuntary, painful contractions of skeletal muscle (Norris 1957; Jansen 1991a; El-Tawil 2010) 
Description of the intervention
Many interventions are available for lower limb muscle cramps. The most common interventions can be broadly categorised as drug or non-drug. 
Why it is important to do this review
Management of leg cramps can be frustrating (Riley 1995) and difficult (Butler 2002) for physicians and patients alike. Many people experience no benefit from the interventions prescribed (Sontag 1988; Abdulla 1999; Miller 2005) and many more receive no intervention at all (Naylor 1994; Gulich 1998; Abdulla 1999) . Only two Cochrane systematic reviews have focused on interventions for muscle cramps. These reviews assessed the treatment of muscle cramps in pregnancy (Young 2002) and the effectiveness of quinine for muscle cramps (El-Tawil 2010) . Two other reviews, currently in protocol stage, will evaluate intervention for muscle cramp in amyotrophic lateral sclerosis (Weber 2003) and magnesium for skeletal muscle cramps (Garrison 2011). The Cochrane systematic review of quinine for muscle cramps (El-Tawil 2010) concluded that, despite moderate quality evidence that quinine significantly reduces cramp frequency, intensity and cramp days more than placebo, alternative interventions for muscle cramp should be investigated due to the risk of adverse effects. A systematic review of non-drug interventions for lower limb muscle cramps will serve two purposes. Firstly, it will enable healthcare providers, users, and policy decision makers to make better informed decisions about the treatment of lower limb muscle cramps. Secondly, it will identify for researchers interventions that require further evaluation in clinical trials.
O B J E C T I V E S
To evaluate the effectiveness of non-drug interventions for lower limb muscle cramps.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of non-drug interventions for the prevention of lower limb muscle cramps. We excluded trials of acute treatment of muscle cramps. We accepted any diagnosis of cramp unless there was clear contradiction with the broad definition used in this review (cramp as a sudden, involuntary, painful contraction of skeletal muscle). We planned to report definitions of 'cramp' used in included studies in the table Characteristics of included studies. We contacted authors for clarification if: (1) 'cramp' was diagnosed but not defined, (2) authors diagnosed commonly used synonyms for cramp (for example, spasm) or (3) authors described the problem in such a way that we suspected muscle cramp (for example, if they described the problem as a sudden, painful contraction of skeletal muscle).
Types of participants
We included all people (including men, women and children) who experience lower limb muscle cramp. We included cramp during any activity or condition, including (but not limited to) cramp associated with exercise, pregnancy, haemodialysis, sleep and neurological conditions.
Types of interventions
We included all non-drug and non-invasive interventions used for at least four weeks. These may have included, but were not limited to, muscle stretching, splints, massage, warmth, change in sleeping position, placebo, relaxation, footwear, weight loss, compression garments, transcutaneous nerve stimulation, muscle strengthening, regular exercise, and changes to physical activity. We excluded all drug interventions and invasive interventions (including surgery and acupuncture/dry needling). For this review, drug interventions included any intervention taken orally (such as tablets, capsules, tonics), by injection, by rectal or vaginal suppository or by inhalation. We also excluded topically applied medicines (for example glyceryl trinitrate patches); however, topically applied preparations that are not thought to alter body function directly and independently (such as oils used in massage) were eligible for inclusion. We also excluded reflexology. We only included trials that included drug or invasive interventions if at least two other groups did not receive a drug or invasive intervention.
Types of outcome measures Primary outcomes
• Cramp frequency, measured as number of cramps per week
When analysing cramp frequency, we planned to use change from baseline frequency where possible. If change scores with measures of variability were not available for all trials included in the same analysis, we planned to combine change scores and follow-up values using standardised mean differences (SMD).
Secondary outcomes
• Adverse outcomes • Cramp severity, including pain severity (measured using any validated pain assessment tool, for example, a visual analogue scale) and duration of cramp (measured in seconds)
• Health-related quality of life (measured by any validated assessment tool, for example, SF-36 survey)
• Quality of sleep (measured by any validated assessment tool, for example, MOSleep survey)
• Participation in activities of daily living, including physical activity (measured by any validated assessment tool)
If data from only one study were included in an analysis, we measured the outcome at the time point used in the original study. If data from more than one trial were included in an analysis, we planned to group the outcomes in the time points 'four weeks to three months' and 'more than three months'. In this instance, the time point 'more than three months' was planned to be the primary outcome and the time point 'four weeks to three months' was planned to be a secondary outcome. We planned to standardise all outcome data combined in meta-analysis to an appropriate follow-up period, for example, cramps per week after four months combined with cramps per week after six months. 'Summary of findings' tables were prepared for the outcomes cramp frequency, cramp pain severity, cramp duration and adverse effects.
Search methods for identification of studies Electronic searches
We searched the Cochrane Neuromuscular Disease Group Specialized Register (13 September 2011) using the terms 'cramp', 'spasm', 'contracture', 'charley horse' and 'lower limb', 'lower extremity', 'foot', 'calf ', 'leg', 'thigh', 'gastrocnemius', 'hamstring' or 'quadriceps'. We also searched CENTRAL (2011, Issue 3), MED-LINE (January 1966 to August 2011) and EMBASE (January 1980 to August 2011). The detailed search strategies are in the appendices: Appendix 1 (MEDLINE), Appendix 2 (EMBASE) and Appendix 3 (CENTRAL). There were no language or publication restrictions.
Searching other resources
We checked the references of the included study for other suitable trials. The first author of the included study was contacted via email to assist in identifying relevant unpublished and published trials.
Data collection and analysis
Selection of studies
Two authors (FB and KW) independently assessed the titles and abstracts of all trials identified by the search. The same two authors then independently assessed for inclusion full-text copies of potentially relevant studies. Authorship and results were not masked. We resolved disagreements by discussion between review authors or, when necessary, arbitration by a third review author (JB). We planned to contact study authors if arbitration by the third reviewer did not resolve the dispute. If this was unsuccessful, we were to report the disagreement in the review. This was not required. We sought guidance from the Cochrane Neuromuscular Group regarding the eligibility of one trial (Coppin 2005) for inclusion. Guidance was provided and followed.
Data extraction and management
One review author (FB) extracted data from the published report using a standardised, pilot tested form and a second review author (KW) performed cross checks. We contacted the study authors as necessary to provide missing information or clarifications. We planned to resolve disagreements by discussion between review authors or, if necessary, arbitration by a third review author (JB). This was not required.
Assessment of risk of bias in included studies
Two review authors (FB and KW) independently rated risk of bias of the included trial using the following criteria as described in the Cochrane Handbook of Systematic Reviews of Interventions (Higgins 2011):
• sequence generation;
• concealment of allocation;
• blinding;
• incomplete data;
• selective outcome reporting;
• other sources of bias, such as financial conflicts of interest and single author or single centre trials.
Each criterion was assigned a judgement of 'high risk', 'low risk' or 'unclear risk' relating to the risk of bias for that entry. 'Unclear risk' indicates an unclear or unknown risk of bias; or if an entry is not relevant to the study at hand. Results are presented in the 'Risk of bias' table. A 'Risk of bias summary' figure was generated using Review Manager 5 to present all of the judgements in a crosstabulation of study by entry. If we were required to contact study authors for missing information regarding risk of bias, we planned to ask open-ended questions to reduce the risk of leading, for example the open-ended question 'How did you decide which treatment the next patient should receive?' was to be used in preference to 'Did you conceal the allocation sequence?'. This was not required.
Measures of treatment effect
Where possible, we analysed continuous data using mean differences (MD) and 95% confidence intervals (CI). If meta-analysis was required to pool data derived from different measurement scales, we planned to perform standardised mean difference (SMD) analyses. This was not required. We analysed count data (for example number of muscle cramps) as continuous data (mean number of cramps per person per week). We planned to report results for dichotomous data as risk ratios (RR) with 95% CI.
Unit of analysis issues
We planned to include cross-over trials; however, only data from the first phase of intervention were to be considered, as clinical trials of interventions for muscle cramp have detected significant carryover effects (particularly for quinine) (Dunn 1993; Jansen 1997; Coppin 2005) and the effectiveness of washout periods for interventions for muscle cramps is unknown. Due to the substantial and variable carryover effect of quinine, we excluded studies that discontinued quinine less than three months prior to intervention within the trial.
Dealing with missing data
Where available, we planned to extract data from intention-totreat analyses. If the original researchers did not perform intentionto-treat analyses and sufficient raw data were available, we planned to complete intention-to-treat analyses before entering data into the Cochrane statistical package Review Manager (RevMan) 5.1.2 (RevMan 2011), to limit attrition bias.
Assessment of heterogeneity
We planned to assess clinical heterogeneity across trials and if trials were sufficiently clinically homogenous in terms of participants, interventions, and outcomes we would have included them in meta-analysis. We planned to quantify inter-trial statistical inconsistency using I 2 (Higgins 2011). The I 2 value was to be calculated by:
where Q is Cochran's heterogeneity, Chi 2 statistic and df is the degrees of freedom. The Cochran's Q is determined by summing the squared deviations (SDs) of each trial's estimate from the overall meta-analytic estimate and a P value obtained by comparing the statistic with a x 2 distribution with k -1 degrees of freedom (where k is the number of trials). We planned to use the following guide to interpret the I 2 values:
• 0 to 40% might not be important;
• 30 to 60% may represent moderate heterogeneity;
• 50 to 90% may represent substantial heterogeneity;
• 75 to 100% considerable heterogeneity.
If heterogeneity could not readily be explained, we planned to use a random-effects model to incorporate heterogeneous trials in meta-analysis.
Data synthesis
We used RevMan for statistical analyses. One author (FB) entered statistical data into RevMan and a second author (KW) checked the data.
Subgroup analysis and investigation of heterogeneity
Providing sufficient data were available, we planned to perform subgroup analysis according to cramp type/aetiology, for example, rest cramp versus exercise-associated cramp versus haemodialysis cramp versus cramp in people with neuromuscular disease.
Meta-analyses of subgroups were to follow the same methodological principles as the primary analysis. If meta-analyses were performed within multiple subgroups, we planned to compare the magnitude of effect estimates for subgroups informally between groups. We were to have considered non-overlap of summary estimate CIs to indicate statistical significance. If CIs overlapped to a small degree, we would have considered the possibility of a statistically significant difference (Higgins 2011).
We did not plan to compare the statistical significance of the pooled effect estimates for individual subgroups as the likely unequal information loading subgroups would have affected the power to detect effects (Higgins 2011).
Sensitivity analysis
We planned to perform sensitivity analyses by including only studies of high methodological quality (low to moderate risk of bias).
If we had found all trials to have a high risk of bias, we planned to perform sensitivity analyses by excluding trials not concealing allocation or blinding the participants. If one or more outliers were found to contribute to heterogeneity, and a reason for the outlying result was apparent, we planned to perform analyses both with and without outlying trials as a component of sensitivity analysis (Higgins 2011).
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. 
Results of the search
Included studies
One trial with a total of 191 participants was eligible for inclusion (Coppin 2005). Details of this trial are presented in the table
Characteristics of included studies. This trial was identified by electronic searching. All participants were age 60 years or over and had received a repeat prescription from their general practitioner of quinine for nighttime cramps in the preceding three months. Participants were allocated to one of four groups: (1) advised to discontinue taking quinine and begin a calf stretching program; (2) advised to discontinue taking quinine and begin a placebo stretching program; (3) advised to continue taking quinine and begin a calf stretching program; and (4) advised to continue taking quinine and begin a placebo stretching program. No washout period was provided for those participants advised to discontinue taking quinine, which excludes two groups from this review. This review includes only the 97 participants who were advised to continue taking quinine. Of these participants, 49 (51%) were male, the mean age was 74.3 years (standard error of the mean (SEM 0.6)) and at baseline the recalled number of cramps in the previous four weeks was 10.4 (SEM 1.76). Each participant was allocated to either a calf stretching or placebo stretching group. Calf stretches were performed by leaning into a wall for 10 s three times per day. The stretches and placebo stretches are described in detail in the table Characteristics of included studies. After six weeks, participants were told that they could continue the stretching exercises if they wished and also decide themselves whether or not to continue taking quinine tablets. Participants in the placebo stretching group were also given an instruction sheet describing the stretching exercise program. Published results in Coppin 2005 are only for 1, 2 and 12 week followup and there is no separation within the stretching and placebo stretching groups of those participants who continued quinine versus those who discontinued quinine.
In an attempt to avoid the confounding effects of changing interventions and to exclude participants who were advised to discontinue taking quinine, trial authors were contacted to provide six-week follow-up data for the participants who were advised to continue taking quinine in the stretching and placebo stretching groups. Only 12 weeks follow-up data were provided for the primary outcome 'number of cramps in the last four weeks'.
Excluded studies
We excluded 
Risk of bias in included studies
Assessment of risk of bias for Coppin 2005 is described in the table Characteristics of included studies and is summarised in Figure 1 . 
Allocation
Allocation order was concealed using sealed, numbered, opaque envelopes containing intervention instructions.
Blinding
Participants were blinded to their group allocation by comparing calf muscle stretching to "placebo exercise", which "was devised to be of comparable duration and simplicity to the intervention stretching exercise, but was passive and involved negligible stretching of the muscles of the calf and foot". Researchers "sought to minimise intervention contamination by terming the stretching and placebo exercises as 'standing' and 'lying' exercises, respectively". Outcome assessors were blinded by using self-report postal questionnaires.
Incomplete outcome data
In the 12-week data provided by the authors, data is missing for one participant from the intervention group and two participants from the control group. Reasons for missing data are not provided.
Selective reporting
The online protocol (ISRCTN26051665) states that outcomes would include duration of leg cramps and subsequent GP atten-dance. Data for these outcomes are not provided in the published paper.
Other potential sources of bias
After 12 weeks, participants were asked to recall how many night cramps they had experienced in the preceding 4 weeks. Participants might be subject to recall bias. As discussed under Included studies, participants were allowed to swap intervention groups after six weeks. When contacted, trial authors provided only 12-week follow-up data and did not respond to further request for six-week follow-up data. Permitted treatment changes after six weeks included discontinuation of quinine, discontinuation of any form of stretching exercise and, if the participant was initially allocated to the placebo stretching group, beginning the stretching exercise program. The study does not report how many of the participants within the stretching and placebo stretching groups included in this review modified their intervention at six weeks. This seriously limits the interpretability and clinical applicability of results.
Effects of interventions
See: Summary of findings for the main comparison Calf muscle stretching versus placebo stretching for lower limb muscle cramps In Coppin 2005, of those participants advised to continue taking quinine, 49 were allocated to the stretching group and 48 were allocated to the placebo stretching group. No participant was lost to follow-up, yet owing to incomplete data, we included only 48 participants from the stretching group and 46 participants from the placebo stretching group in the analysis. As change-from-baseline frequencies and SD were not available for data analysis, plain follow up scores and SD were used. After 12 weeks, participants were asked to recall how many cramps they had experienced in the previous four weeks. The difference in mean number of recalled cramps between the stretching group (mean 10.02, SD 17.67) and the placebo stretching group (mean 8.83, SD 17.23) was not statistically significant (MD 1.19, 95% CI -5.86 to 8.25, Analysis 1.1). There were no "significant adverse effects" reported. No definition of "significant adverse effects" was provided.
D I S C U S S I O N
This review included only one study. The included study aimed to assess the effect of (1) calf stretching exercises and (2) cessation of quinine on nighttime muscle cramp. Only the effect of calf stretching exercises was considered in this review. This study compared 49 people randomly allocated to a lean-to-wall calf stretching group with 48 people randomly allocated to a placebo (fake) stretching group. Both groups performed their stretches for 10 s three times per day. All participants were also taking quinine for their muscle cramps. After six weeks, participants could decide for themselves whether or not to continue with their allocated stretches and quinine tablets. Outcome data were provided by the authors, but only for 12-week follow-up. At the 12-week followup, participants were asked how many cramps they had experienced in the last four weeks.
Summary of main results
There is very low quality evidence that lean-to-wall calf muscle stretching held for 10 s three times per day does not reduce frequency of nighttime cramp (of unspecified muscles) after 12 weeks in people aged 60 years and over who have also been prescribed quinine for muscle cramping. See Summary of findings for the main comparison.
Overall completeness and applicability of evidence
The evidence for the use of non-drug therapies for lower limb muscle cramps is overwhelmingly incomplete. Of all types of lower limb muscle cramp (for example, cramp associated with exercise, pregnancy, haemodialysis, sleep and neurological conditions) and of all available non-drug therapies (for example, muscle stretching, massage, weight loss, physical exercise, avoiding physical fatigue, heat therapy, compression garments, night ankle dorsiflexion splints, sensory nerve stimulation, footwear changes, and changes to sleeping and sitting position), only one small study has investigated calf muscle stretching for nighttime cramp in people aged 60 years and over who had been given a repeat prescription of quinine for night cramps in the previous three months. The applicability of the available evidence is severely limited by deficiencies in study design. These limitations are discussed in more detail below.
Quality of the evidence
The quality of the evidence included in this review is very low Figure 1 . Some strengths of the trial include: (1) the allocation order was concealed (that is, researchers and participants did not know to which group they would be allocated before agreeing to participate) and (2) participants were blinded to their group allocation (that is, participants were not aware if they were in the true stretching or fake stretching group). Some weaknesses of the trial include: (1) there is unexplained missing data for one participant in the true stretching group and two participants in the fake stretching group and (2) outcomes reported in the published paper are different to those listed in the registered online protocol (research plan). Other weaknesses and limitations of the study are discussed below.
Limitations of the study design
After six weeks, participants in both the stretching and placebo stretching groups were allowed to swap or discontinue stretching treatments and to decide for themselves whether or not to continue taking quinine. As we included only those participants who were advised at baseline to continue taking quinine, no published data were suitable for use in analysis and trial authors provided only 12-week follow-up data when contacted. It is not known how many participants in the stretching and placebo stretching groups included in this review swapped or discontinued stretching exercises, or discontinued taking quinine after six weeks. This study design does not reflect clinical practice and seriously limits interpretation as it is impossible to isolate the effect of the intervention assigned at baseline. The portion of the published study included in this review is underpowered to detect a clinically important difference between groups according to the included study author's power calculations. Coppin 2005 estimated a minimum sample size of 128 participants with complete outcomes, well above the 94 participants with complete outcomes included in this review.
Limitations of the participants
Coppin 2005 recruited participants aged 60 years and over who had been given a repeat prescription of quinine for night cramps in the previous three months. It is not known whether or not the quinine was effective. No inclusion criterion addressed the number of cramps affecting the participant in a defined period (for example, one week). It is possible that some of the included participants no longer experienced nighttime muscle cramp, perhaps due to the effect of the prescribed quinine tablets. Also, no inclusion criterion addressed the location of the nighttime cramp. While nighttime cramp often affects the calf muscle, other muscles of the lower limb and upper limb muscles can be affected. It is not known how many of the included participants experienced nighttime calf cramp. This limits the justifiability of offering a stretching program that targeted only the calf muscles.
Limitations of the intervention
The stretching intervention advice offered in Coppin 2005 is described in full in the table Characteristics of included studies. To summarise, participants were asked to stretch both calf muscles at the same time by leaning towards a wall for 10 s, three times throughout the day.
As muscle stretching has never before been evaluated in a RCT for treating muscle cramp, no direct comparisons in the literature can be found. In a systematic review of stretching before or after exercising to reduce delayed onset muscle soreness, risk of injury, and athletic or sporting performance, calf muscle stretching consisted of two separate stretches of soleus and gastrocnemius muscles held for 20 s on each limb, with a total stretch time of 160 s (Herbert 2002). The stretches prescribed in Coppin 2005 may be less intense (by stretching both limbs at the same time) and held for a shorter time than is ideal and than calf stretches routinely recommended in clinical practice. As discussed above, this calf muscle stretching intervention was given to all participants, regardless of the location of their nighttime muscle cramp. This may not reflect standard clinical practice, where stretching therapies are targeted at the affected muscles.
Limitations of the outcome measure
From the description in the published paper, participants were asked in a postal survey 12 weeks from baseline to recall how many night cramps they had experienced in the previous four weeks. This outcome is subject to recall bias. The outcome also does not focus on the number of calf muscle cramps experienced. As the stretching interventions targeted only the calf muscles, the effect of calf muscle stretching on calf muscle cramp is an important, yet unaddressed, component of the outcome measure.
There are no data available on the severity of cramps experienced. This is an important outcome in trials of interventions for muscle cramps, as it is possible that the severity of cramp may reduce without a notable reduction in cramp frequency.
Potential biases in the review process
None
Agreements and disagreements with other studies or reviews
The effect of non-drug therapies for lower limb muscle cramp has never before been systematically reviewed.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Evidence from RCTs is too limited in quantity and quality to provide clinical direction for the use of any type of non-drug therapy for any type of lower limb muscle cramps.
Implications for research
This review highlights the urgent need for rigorously designed RCTs to evaluate the effectiveness of non-drug therapies for lower limb muscle cramps. Future research should explore the effectiveness of a wide range of the available non-drug therapies for cramp associated with exercise, pregnancy, haemodialysis, sleep and neurological conditions. Published reports of future trials should include high quality descriptions of all aspects of methodology to enable appraisal and interpretation of results. Outcomes should at least include cramp severity and frequency, and measures of frequency should not rely on participants retrospectively recalling the number of cramps experienced over a period of time.
More research is required to determine clinical important difference values for people experiencing nighttime muscle cramp to improve power calculations in future research. 
A C K N O W L E D G E M E N T S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Coppin 2005
Methods Factorial design randomised control trial for the first 6 weeks. After 6 weeks, participants were told that they could continue the exercises if they wished and also decide themselves whether or not to continue or resume taking quinine tablets. Participants were also given an instruction sheet describing the exercise programme and confirming the advice Data collection took place between January 1999 and September 2001 Participants Participants were recruited through 28 general practices in southern England. Database searching at each practice identified potential participants, who were then contacted by letter Inclusion criteria: people aged 60 years and over who had been given a repeat prescription by their general practitioner of quinine for nocturnal (night) cramps in the previous 3 months. Cramp was not defined in the published report Exclusion criteria: People with conditions significantly limiting their ability to undertake the stretching exercises (for example, severe osteoarthritis); leg pain that might be confused with cramp (for example, severe peripheral vascular disease); inability to reliably report on symptoms (for example, dementia); and patients who described being previously taught leg exercises aimed at preventing cramp Interventions Participants were given advice to either continue or discontinue taking quinine tablets (this review includes data only from participants who were allocated to continue quinine use) and to undertake a daily programme of either stretching or placebo exercises for which they received training The placebo exercise was devised to be of comparable duration and simplicity to the intervention stretching exercise, but was passive and involved negligible stretching of the muscles of the calf and foot. An attempt was made to minimise intervention contamination by terming the stretching and placebo exercises as 'standing' and 'lying' exercises, respectively Patients were then shown how to complete a 6-week diary record One week later the nurse telephoned the patient to check that they were coping with the diary recording. Intervention advice was not repeated For the stretching exercise the nurse gave participants the following instruction, "First remove your shoes, then stand facing a wall 2 to 3 feet away so that the tips of your fingers are just touching the wall. Lean forward keeping your heels in contact with the floor, keep your body straight and use your arms to control your forward tilt until you feel a moderately intense, but not painful, 'pulling sensation' in your calf muscles. This stretching position should be held for 10 seconds (count 1 elephant, 2 elephants, etc.). Stand upright and relax for 5 seconds, then repeat the stretch for a further 10 seconds. Carry out this sequence three times spread through each day" For the non-stretching exercise the nurse advised participants as follows, "First lie face up on your bed or on the floor so that your legs are out straight. Gently bend your knees up and move them towards your chest keeping your feet flat on the bed or floor. When your feet are as near your bottom as you can get them without causing discomfort, hold that position for 10 seconds (count 1 elephant, 2 elephants, etc.). Straighten your legs out and relax for 5 seconds then repeat the exercise for a further 10 seconds. Carry out
